The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features

被引:0
|
作者
Santoro, Angela [1 ,2 ]
Angelico, Giuseppe [3 ]
Travaglino, Antonio [4 ]
Inzani, Frediano [5 ,6 ]
Spadola, Saveria [3 ]
Pettinato, Angela [7 ]
Mazzucchelli, Manuel [8 ]
Bragantini, Emma [9 ]
Maccio, Livia [9 ]
Zannoni, Gian Franco [1 ,2 ]
机构
[1] Univ Cattolica Sacro Cuore, Pathol Inst, I-00168 Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Woman & Childs Hlth & Publ Hlth Sci, Pathol Unit, I-00168 Rome, Italy
[3] Kore Univ Enna, Dept Med & Surg, I-94100 Enna, Italy
[4] Univ Insubria, Dept Med & Technol Innovat, Pathol Unit, Varese, Italy
[5] Univ Pavia, Dept Mol Med, Anat Pathol Unit, I-27100 Pavia, Italy
[6] Fdn IRCCS San Matteo Hosp, I-27100 Pavia, Italy
[7] AOE Cannizzaro, Dept Pathol Anat, Via Messina,829, I-95126 Catania, Italy
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Anat Pathol, Catania, Italy
[9] Santa Chiara Hosp, Unit Surg Pathol, APSS, Trento, Italy
关键词
Ovarian cancer; P53; BRCA; Homologous recombination repair; TCGA; TILs; PLATINUM-RESISTANT OVARIAN; FOLATE RECEPTOR-ALPHA; ANTITUMOR-ACTIVITY; DNA-REPAIR; PHASE-II; T-CELLS; CANCER; EXPRESSION; MUTATIONS; ANTIBODY;
D O I
10.1016/j.critrevonc.2024.104603
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FR alpha) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Morse, Christopher B.
    Norquist, Barbara M.
    Harrell, Maria I.
    Agnew, Kathy J.
    Gray, Heidi J.
    Urban, Renata R.
    Garcia, Rochelle L.
    Goff, Barbara A.
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 389 - 392
  • [2] Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach
    Khashaba, Marwa
    Fawzy, Mohamed
    Abdel-Aziz, Azza
    Eladawei, Ghada
    Nagib, Reham
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2022, 34 (01)
  • [3] Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
    Kurman, R. J.
    ANNALS OF ONCOLOGY, 2013, 24 : 16 - 21
  • [4] Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis
    Li, Hong-Xia
    Lu, Zhao-Hui
    Shen, Keng
    Cheng, Wen-Jun
    Malpica, Anais
    Zhang, Jing
    Wei, Jian-Jun
    Zhang, Zhi-Hong
    Liu, Jinsong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (03): : 848 - 857
  • [5] Molecular Management of High-Grade Serous Ovarian Carcinoma
    Punzon-Jimenez, Paula
    Lago, Victor
    Domingo, Santiago
    Simon, Carlos
    Mas, Aymara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [6] Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor
    Kanno, Kosuke
    Nakayama, Kentaro
    Razia, Sultana
    Islam, Sohel Hasibul
    Farzana, Zahan Umme
    Sonia, Shahataj Begum
    Sasamori, Hiroki
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Imamura, Kayo
    Ishikawa, Noriyoshi
    Kyo, Satoru
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (09) : 9376 - 9385
  • [7] Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
    Ducie, Jennifer
    Dao, Fanny
    Considine, Michael
    Olvera, Narciso
    Shaw, Patricia A.
    Kurman, Robert J.
    Shih, Ie-Ming
    Soslow, Robert A.
    Cope, Leslie
    Levine, Douglas A.
    NATURE COMMUNICATIONS, 2017, 8
  • [8] Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma
    Dai, Ying
    Sun, Chengdu
    Feng, Yi
    Jia, Qingzhu
    Zhu, Bo
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (08) : 3979 - 3986
  • [9] Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
    Arend, Rebecca C.
    Londono, Angelina I.
    Montgomery, Allison M.
    Smith, Haller J.
    Dobbin, Zachary C.
    Katre, Ashwini A.
    Martinez, Alba
    Yang, Eddy S.
    Alvarez, Ronald D.
    Huh, Warner K.
    Bevis, Kerri S.
    Straughn, J. Michael, Jr.
    Estes, Jacob M.
    Novak, Lea
    Crossman, David K.
    Cooper, Sara J.
    Landen, Charles N.
    Leath, Charles A., III
    MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 813 - 824
  • [10] Stemness in high-grade serous carcinoma of tubo-ovarian origin causes multiple immunohistochemical pitfalls: a case report
    Van Bockstal, Mieke R.
    Augusto, David
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (12) : 845 - 846